Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_assertion type Assertion NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_head.
- NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_assertion description "[These results suggest that the combination of a PI3K inhibitor and a PSMA-targeted protein synthesis inhibitor toxin represents a promising novel strategy for advanced prostate cancer therapy that should be further investigated.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_provenance.
- NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_assertion evidence source_evidence_literature NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_provenance.
- NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_assertion SIO_000772 24204196 NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_provenance.
- NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_assertion wasDerivedFrom befree-2016 NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_provenance.
- NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_assertion wasGeneratedBy ECO_0000203 NP1126016.RAK516VJmZchQEhS9K-R36baZSRhX1Yj48b8VcIK5-uuk130_provenance.